文献速递神经肿瘤

基于价值驱动结局数据库评估经蝶入路垂体瘤切除术的费用驱动因素

Assessment of Cost Drivers in Transsphenoidal Approaches for Resection of Pituitary Tumors Using the Value-Driven Outcome Database.
PubMed 文献 · World Neurosurg · 2017-06-02

该研究回顾性分析了2012年7月至2016年9月犹他大学272例经蝶入路垂体腺瘤切除术患者,评估总费用、亚类费用及潜在费用驱动因素。结果显示设施利用是总体费用的最强驱动因素,其中神经重症监护病房费用占30.7%。作者建议将低风险患者分层至中间护理单元并缩短住院时间以降低成本。

要点

  • 设施利用占总费用的60%,是最强费用驱动因素。
  • 神经重症监护病房费用占设施费用的30.7%。
  • 作者建议将低风险患者分层至中间护理单元并缩短住院时间。

核心结论

  • 设施利用以及药品、耗材/植入物、影像和实验室费用是经蝶垂体瘤切除术总体费用的重要驱动因素。
  • 设施利用是比任何其他护理方面更强的费用驱动因素。

研究设计与样本

  • 回顾性综述,纳入2012年7月至2016年9月在犹他大学接受经蝶入路垂体腺瘤切除术的患者,共272例,平均年龄51.5岁±17.7,男性占45.6%,平均住院时间4天±4。

主要发现

  • 总费用构成:设施利用占60%,医师专业费用占16%,药品占11%,耗材和植入物占7%,实验室检查占5%,影像占1%。
  • 设施费用由神经重症监护病房(30.7%)、神经外科手术室(16.6%)和神经外科病房(11.2%)驱动。
  • 调整住院时间和美国麻醉医师协会分级后,多变量线性回归显示总体费用受设施利用(ρ=0.98,P=0.001)、药品(ρ=0.71,P=0.001)、耗材和植入物(ρ=0.51,P=0.0001)、影像(ρ=0.51,P=0.0001)和实验室(ρ=0.79,P=0.001)费用影响。
  • 前10位异常值患者占总费用的18.7%,所有患者的平均费用为0.24%±0.29。

临床怎么用

  • 作者建议将低风险患者分层至中间护理单元并缩短住院时间以降低成本。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Reducing health care costs while improving quality of care has become imperative in neurosurgical care. The Value-Driven Outcome database at the University of Utah identifies cost drivers and tracks changes over time. METHODS: Retrospective review was performed for transsphenoidal resections of pituitary adenomas from July 2012 to September 2016. Total cost, subcategory costs, and potential cost drivers were evaluated. RESULTS: There were 272 patients (mean age 51.5 years ± 17.7, 45.6% male) with mean length of stay of 4 days ± 4 evaluated. Total costs included facility utilization (60%), physician professional fees (16%), pharmacy (11%), supplies and implants (7%), laboratory studies (5%), and imaging (1%). Facility costs were driven by neurocritical care unit (30.7%), neurosurgical operating room (16.6%), and neurosurgical floor (11.2%) costs. Multivariable linear regression, after adjusting for length of stay and American Society of Anesthesiologists grade, showed that overall cost was heavily influenced by facility utilization (ρ = 0.98, P = 0.001), pharmacy (ρ = 0.71, P = 0.001), supplies and implants (ρ = 0.51, P = 0.0001), imaging (ρ = 0.51, P = 0.0001), and laboratory (ρ = 0.79, P = 0.001) costs. The top 10 outlier patients accounted for 18.7% of total costs (mean cost for all patients 0.24% ± 0.29). CONCLUSIONS: Our results highlight the importance of facility utilization and pharmaceutical, supply/implant, imaging, and laboratory costs as overall cost drivers during transsphenoidal pituitary tumor resection. Facility utilization was a stronger cost driver than any other aspect of care. Strategies to mitigate cost include stratifying low-risk patients to an intermediate care unit and reducing length of stay.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Karsy M, Brock AA, Guan J, et al. Assessment of Cost Drivers in Transsphenoidal Approaches for Resection of Pituitary Tumors Using the Value-Driven Outcome Database. World Neurosurg. 2017. PMID: 28583451. doi:10.1016/j.wneu.2017.05.148

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。